Lilly’s Obesity Pill Foundayo Shows Heart Safety as FDA Seeks More Data

53 articles · Updated · Investor's Business Daily · Apr 17

Eli Lilly's new obesity pill, Foundayo, has shown a favourable safety profile and reduced cardiovascular risks in a major Phase 3 trial.
The ACHIEVE-4 study found Foundayo lowered the risk of heart attack, stroke, or cardiovascular death by 16% compared to insulin glargine.
The FDA has approved Foundayo for weight loss but requested more long-term safety data, including on liver and thyroid cancer risks.

Foundayo's approval was fast-tracked, but what long-term health risks, like thyroid cancer, remain unknown to patients?

With its 'take anytime' advantage, can Lilly's new pill truly dethrone Novo Nordisk's established weight-loss drugs?

If new research suggests GLP-1 isn't essential for weight loss, is the entire industry backing the wrong approach?

As weight-loss pills become mainstream, are we solving obesity or creating lifelong pharmaceutical dependency?

With Walmart and Amazon now distributing obesity pills, how will Big Tech reshape pharmaceutical access and patient care?